REMARKS

Favorable reconsideration of this application is requested in view of the above amendments and the following remarks. Claim 6 is pending and has been limited to SEQ ID NOs 10-18 in addition to the editorial revision requested in the Office Action. Claims 1-3 and 7-21 have been cancelled without prejudice or disclaimer. Claims 4-5 were previously cancelled.

A revised sequence listing has been provided as requested.

As claim 6 is directed to a polypeptide having an indicated sequence, Applicants submit that the 35 USC 112 first and second paragraph rejections have been rendered moot. Applicants are not conceding the correctness of the rejections.

Applicants also submit that the Mumm and Roberts references cited in the anticipation rejections fail to teach a polypeptide having a sequence found in SEQ ID NOs 10-18, and therefore the anticipation rejections are moot. Applicants again are not conceding the correctness of the rejections.

In view of the above, early issuance of a notice of allowance is solicited. Any questions regarding this communication can be directed to the undersigned attorney, Douglas P. Mueller, Reg. No. 30,300 at (612) 455-3804.

52835
PATENT TRADEMARK OFFICE

Dated: June 26, 2009

Respectfully submitted,

HAMRE, SCHUMANN, MUELLER & LARSON, P.C.

P.O. Box 2902

Minneapolis, MN 55402-0902

(612) 455-**\$**800

By:

Douglas P. Mueller Reg. No. 30,300

DPM/mz